Angioslide Announces First Successful Below-The-Knee Procedures in the US

CAESAREA, Israel, July 11, 2012 /PRNewswire/ –

Angioslide Ltd., a provider of Embolic Capture Angioplasty solutions, today announced
the successful deployment of a 3X100mm PROTEUS device for treating Peripheral Artery
Disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, IN.
Accommodating a 0.014″ guide-wire, the new device allows physician to perform a PTA
revascularization in BTK vessels while capturing and removing embolic particles.

“With PROTEUS having been successfully used to treat lesions in the SFA (superficial
femoral artery), I had the opportunity to deploy the device in BTK procedures,” said Dr.
Prakash Makam of Community Hospital (Munster, IN). “It is an effective, easy to use tool
that provides an alternative for removal of embolic material, including micro particles,
that could compromise downstream vasculature flow and perfusion to the foot. This is
especially important when treating high-risk, diabetic and critical limb ischemia (CLI)
patients.”

Angioslide’s proprietary technology combines the functionality of a balloon
angioplasty device with the addition of capture and removal of particles released during
intervention. Capture of embolic material is enabled by the inward folding of the balloon
through a dedicated handle, which creates a suction effect that pulls embolic material
into the cavity. When retrieved through the sheath, PROTEUS removes the captured material
from the body.

“We are excited to provide a solution for capture and removal of embolic debris for
below-the-knee intervention, where the clinical consequences of emboli are amplified by
small vessel diameter,” said Lihu Avitov, CEO, Angioslide. “The Current set of tools
available on the market for BTK intervention are suboptimal, and we look forward to
meeting this important clinical need. With the successful completion of our first cases in
the US, we will introduce our product to a wider number of centers.”

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed
a unique Embolic Capture Angioplasty solution, PROTEUS(TM), which provides a combination
of PTA balloon and embolic suction mechanism. The PROTEUS(TM) device addresses an unmet
need for an easy-to-use, efficient and cost-effective embolic removal solution for the
peripheral vascular disease market. It is the first device of its kind to receive FDA
clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial,
peroneal, and profunda arteries). The device has also received European CE Mark approval
for lower limb use and is being marketed in selected regions in Europe. Angioslide
headquarters are located in Caesarea, Israel, and Denver Colorado. For more information
visit our website at http://www.angioslide.com

        Contact:

        Shira Doron
        Marketing Director
        Mobile: +972-54-9011134
        Email: shirad@angioslide.com

SOURCE Angioslide Ltd.